NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT04155749: Phase 1 : CART-ddBCMA - Master Protocol for Cell Therapies in Multiple Myeloma
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)
NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
NCT03158688: Phase 3 - Carfilzomib, Daratumumab and Dexa for relapsed Multiple Myeloma. (CANDOR)